Search alternatives:
nmon decrease » nn decrease (Expand Search), mean decrease (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
nmon decrease » nn decrease (Expand Search), mean decrease (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
-
101
Changes to chromatin state with PRMT5 inhibition.
Published 2021“…(D) Immunoblot analysis indicates a time dependent decrease in MYC protein after treatment with C220 in 17–71 (100 nM) and CLBL-1 (20 nM). …”
-
102
-
103
20E repressed ILP-mediated cell membrane translocation of HaP60 and HaP110, dephosphorylated HaP60 and HaP110, and decreased their interaction.
Published 2021“…Insulin (5 μg/mL for 1 h); PBS as control of insulin; 20E (5 μM for 6 h); DMSO as control of 20E; TPI-1 (100 nM). …”
-
104
-
105
Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s.
Published 2023“…<p>Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s.</p>…”
-
106
Selectivity of PRMT5 inhibition with C220.
Published 2021“…For all cell lines, effects of PRMT5 inhibition with C220 treatment on biomarkers of PRMT5 activity shows a dose-dependent decrease in global marks of symmetric di-methylarginine (SDMA) and symmetric di-methylation of histone H4 arginine-3 (H4R3me2s) with a minimal effect to PRMT5 or global asymmetric di-methylarginine (ADMA). …”
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease: A randomized clinical trial
Published 2022“…<div><p>Abstract Hepatoprotective effects of many herbal agents have been reported in animal studies and clinical trials. In this study, five hepatoprotective plants with potent antioxidant, anti-inflammatory, and hypolipidemic effects were chosen to prepare a polyherbal compound for managing NAFLD. …”
-
116
-
117
-
118
-
119
-
120